Valent Technologies, LLC
1 clinical trials · Sponsor
◉ Watch Valent Technologies, LLC
| Record | Firm | Date |
|---|---|---|
| Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors (NCT04337177) | Valent Technologies, LLC | 2021-10-25 |
Track Valent Technologies, LLC automatically
Every clearance here is in the API, with alerts when new ones post.